2022, Number 1
<< Back Next >>
Rev Acta Médica 2022; 23 (1)
Gliomas: an urgent need for a new classification in Cuba
Moore ZT, Arteaga HE, García MG
Language: Spanish
References: 5
Page:
PDF size: 132.27 Kb.
Text Extraction
No abstract.
REFERENCES
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021;71(3):209-49. DOI: https://doi.org/10.3322/caac.21660
Anuario Estadístico de Salud 2020. Bibliot Virt Sal Cuba. 2020 [acceso: 5/12/2021]. Disponible en: http://bvscuba.sld.cu/anuario-estadistico-de-cuba/
Li L, Wang Y, Li Y, Fang S, Jiang T. Role of molecular biomarkers in glioma resection: a systematic review. Chin Neurosurg J. 2020;6(1):18. DOI: https://doi.org/10.1186/s41016-020-00198-x
Lee SC. Diffuse gliomas for nonneuropathologists: The New Integrated Molecular Diagnostics. Arch Pathol Lab Med. 2018;142(7):804-14. DOI: https://doi.org/10.5858/arpa.2017-0449-RA.
Mellinghoff IK, Peters KB, Cloughesy TF, Maher EA, Janku F. Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population. J Clin Oncolog. 2020 [acceso: 5/12/2021];38(15_suppl):2504. Disponible en: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.2504
Full text